Catalyst forecasts 21-26% FIRDAPSE revenue growth in 2026 while expanding AGAMREE market penetration
Source: SeekingAlpha
2026-02-26 15:28:43 ET
More on Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
- Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs
- Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Catalyst Pharmaceuticals, Inc.
Read the full article on Seeking Alpha
For further details see:
Catalyst forecasts 21–26% FIRDAPSE revenue growth in 2026 while expanding AGAMREE market penetration
Catalyst Pharmaceuticals Inc.
NASDAQ: CPRX
CPRX Trading
3.93% G/L:
$24.62 Last:
224,352 Volume:
$24.10 Open:
CPRX Latest News
March 06, 2026 08:03:00 am
Catalyst Pharmaceuticals to Showcase Real?World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
February 25, 2026 04:07:55 pm
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
February 24, 2026 08:03:00 am
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
CPRX Stock Data
$2,973,250,642
121,191,614
0.23%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Coral Gables
